Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257
This is a single-center prospective exploratory translational study including treatment-naive patients affected by ES-SCLC eligible to first line treatment with ACE. Liquid biopsies were longitudinally collected at key time points: T0 (baseline evaluation), T1 (after the first therapy cycle), T2 (after the second therapy cycle), and T3 (at disease progression). NGS cell-free (cf) DNA analysis was performed by the AVENIO ctDNA Expanded kit and shallow whole genome sequencing (sWGS)